A randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of orally administered GLPG3667 once daily for 24 weeks in adult subjects with dermatomyositis
This research study is looking at a new oral medicine, GLPG3667, for adults who have dermatomyositis. Researchers want to find out how well this medicine works, if it's safe to take, and if people can tolerate it without too many side effects. Participants will be randomly given either GLPG3667 or a placebo (a dummy pill with no active medicine) every day for 24 weeks. The main goal is to see if the medicine improves their overall condition, using a special scoring system. They will also keep track of any side effects. This is an early stage of testing, known as a Phase II study, which helps determine if the medicine should be studied further.
At a glance
What is this study about?
This study is designed to explore a new potential treatment, GLPG3667, for adults living with dermatomyositis. Dermatomyositis is a condition that causes muscle weakness and skin rashes. Currently, treatments aim to manage the symptoms, but researchers are always looking for more effective options.
In this study, participants will take either the new medicine (GLPG3667) or a placebo (a tablet that looks the same but contains no active medicine). No one, not even the doctors, will know who is getting the active medicine until the study is over. This is done to make sure the results are as fair and unbiased as possible. The main thing we want to find out is how well GLPG3667 improves the overall condition of people with dermatomyositis over 24 weeks, using a recognised scoring system that looks at various aspects of the illness.
We'll also be carefully checking for any side effects and how the body processes the medicine. Some participants may then have the option to continue into an 'open-label extension' part of the study, where everyone receives the active medicine, allowing researchers to gather more information over a longer period.
Key takeaways
- This study is for adults with dermatomyositis.
- It's testing a new daily medicine called GLPG3667.
- You might receive the medicine or a placebo (dummy pill).
- The study lasts for 24 weeks, with a possible extension.
- It will check if the medicine improves symptoms and if it's safe.
- Participation involves regular clinic visits and assessments.
Who may be eligible?
To join this study, you must be an adult aged 18 years or older. Both men and women can take part.
Beyond these basic requirements, there will be more specific medical criteria that your doctor will need to check. These criteria are in place to make sure the study is safe for you and that the results are as clear as possible. For example, they will need to confirm your dermatomyositis diagnosis and check for any other health conditions or medications you might be taking that could affect your participation.
It's important to discuss your full medical history with the study team. They will be able to tell you if this particular study is a good fit for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you been diagnosed with dermatomyositis?
- Are you able to attend regular clinic appointments?
- Are you comfortable potentially taking a placebo for 24 weeks?
- Are you willing to follow all study instructions and procedures?
What does participation involve?
If you decide to take part, you would be assigned by chance to either receive the new medicine or a placebo pill each day for 24 weeks. During this time, you would have regular visits to the study clinic. These visits would include physical examinations, blood tests, and assessments to see how your dermatomyositis is changing and to check for any side effects. You might also complete questionnaires to describe your symptoms and how you are feeling.
After the initial 24 weeks, some participants might have the opportunity to continue taking the active medicine for longer in an 'open-label extension' phase, bringing the total duration up to 52 weeks. Throughout the study, the research team will explain everything and support you.
Potential risks and benefits
Locations (10)
- —UnverifiedGermany
- —UnverifiedItaly
- —UnverifiedRomania
- —UnverifiedFrance
- —UnverifiedBulgaria
- —UnverifiedCroatia
- —UnverifiedBelgium
- —UnverifiedSpain
- —UnverifiedCzechia
- —UnverifiedPoland
Common questions
What is GLPG3667?
GLPG3667 is the name of a new investigational medicine being tested to see if it can help improve dermatomyositis.
What is a 'placebo'?
A placebo is a dummy pill that looks just like the study medicine but doesn't contain any active ingredients. It's used to fairly compare the new medicine's effects.
Why is this called 'Phase II'?
Phase II means this is an early stage of testing. It's used to check if the medicine works and is safe enough to be studied in larger groups of people later on.
Will I know if I'm getting the medicine or the placebo?
No, during the main part of the study, neither you nor the study doctors will know. This is called 'double-blind' and helps ensure the results are accurate.
What is dermatomyositis?
Dermatomyositis is a rare condition that causes muscle weakness, pain, and a distinctive skin rash.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.